Alzheimer’s disease modeling and drug screening through hiPSC 3D bioprinting
We believe our model will serve to elucidate the early stages of AD by offering a novel perspective that more closely resembles the human AD brain. Furthermore, by using synthetic Aβ enriched bioink and familial AD cell lines that overexpress Aβ our system might offer the chance to study the nucleation of Aβ deposits in real time and mimic the formation of proper Aβ plaques in vitro without the involvement of animal models.
Authors
- Haakon B. Nygaard (ORCID: https://orcid.org/0000-0001-5085-4723)
- Xiujuan Wu (ORCID: https://orcid.org/0000-0002-3692-0891)
- Declan Brennan
- Stefan Wendt (ORCID: https://orcid.org/0000-0002-8754-2464)
- Stefano Sorrentino (ORCID: https://orcid.org/0000-0002-5833-5183)
- Christopher Lee (ORCID: https://orcid.org/0000-0002-5329-9750)
- Wenji Cai (ORCID: https://orcid.org/0009-0003-1127-6571)
Institutions
- University of British Columbia Hospital (CA)
- University of British Columbia (CA)
Publication Details
- Journal
- Alzheimer s & Dementia
- Published
- 2024-12-01
- DOI
- https://doi.org/10.1002/alz.092690
- Primary Topic
- 3D Printing in Biomedical Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00